Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Japan Approves Worlds First iPS Therapies for Parkinsons, Heart Failure Conditional approval granted for Sumitomo Pharmas ...

Conditional genetics and single-embryo RNA-seq show that SETDB1 extinguishes the transient, retroelement-driven transcriptional programs of the totipotent two-cell state to facilitate the exit from ...

In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers. When Elon Musk was at Davos last week, an interviewer asked him if he thought aging ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the “recipe” for the transformation. Researchers at Lund University have now created ...

This is read by an automated voice. Please report any issues or inconsistencies here. Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and ...

New funding led by Goldcrest Capital and Godfrey Capital to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies JUN_01 would be the first ever candidate to ...

At today's online summit hosted by RedmondMag, titled "Cloud Control: Securing Access and Identity in the Microsoft SaaS Stack," longtime Microsoft MVP and Principal Cloud Architect Joey D'Antoni ...

A new paper in the journal Nature reveals an astonishing—and frankly unsettling—feature of some cancer cells: the ability to physically inject mitochondria into their neighboring cells. These ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...

At the 12th Aging Research & Drug Discovery (ARDD) Meeting, which is being held this week in Copenhagen, Life Biosciences Inc. announced that it is developing its partial epigenetic reprogramming ...